Chris Ryan

GC012F/AZD0120 CAR T-cell therapy shows 100% response rate in newly diagnosed multiple myeloma, offering hope for diverse patient groups.

Circulating tumor DNA analysis offers a minimally invasive method for detecting key genetic alterations in hormone receptor-positive breast cancer patients.

Subgroup analyses reveal T-DXd significantly improves invasive disease-free survival in early-stage HER2-positive breast cancer compared to T-DM1, regardless of HER2 expression.

New trials reveal INCA033989 shows promise for treating CALR exon 9-mutated myelofibrosis, demonstrating efficacy and tolerability in patients.

A novel treatment regimen for high-risk mantle cell lymphoma shows impressive response rates and minimal residual disease in early trial results.

Cilta-cel shows promising long-term survival rates in relapsed/refractory multiple myeloma, suggesting potential for a cure in standard-risk patients.

A phase 1 study reveals that sequential CR7-GD2 CAR T-cell therapy administration is better tolerated in pediatric CNS tumor patients than concurrent methods.

Lutetium Lu 177 vipivotide tetraxetan significantly enhances survival in metastatic hormone-sensitive prostate cancer when combined with standard therapies, according to recent trial results.

Atezolizumab significantly enhances disease-free and overall survival in ctDNA-positive muscle-invasive bladder cancer patients, reshaping treatment strategies.

New trial data reveals T-DXd plus THP significantly improves pathologic complete response rates in high-risk HER2-positive early breast cancer patients.

Pimicotinib shows promising long-term efficacy in treating tenosynovial giant cell tumor, achieving high response rates and durable outcomes in patients.

Combination therapy of osimertinib and chemotherapy significantly enhances overall survival in patients with EGFR-mutated advanced lung cancer, surpassing monotherapy outcomes.

Daratumumab-based regimens show significant clinical benefits for newly diagnosed, transplant-ineligible multiple myeloma patients, regardless of frailty changes.

Trifluridine/tipiracil shows potential in improving disease-free survival in colorectal cancer patients post-surgery, despite safety concerns.

New CAR T-cell therapy shows remarkable efficacy in treating relapsed multiple myeloma, achieving high response rates and minimal residual disease negativity.

Combination therapy with savolitinib and osimertinib shows promising results in treating advanced NSCLC with EGFR mutations and MET overexpression.

The ELEVATE trial found combining elacestrant with everolimus or ribociclib is safe and effective for ER+/HER2- metastatic breast cancer.

Adding IMNN-001 to perioperative chemotherapy showed numerical improvements in PFS and OS for newly diagnosed epithelial ovarian cancer, warranting further study.

DeLLphi-304 trial results showed tarlatamab significantly improved PFS and OS over chemotherapy in second-line SCLC, establishing it as a new standard.

Durvalumab plus FLOT improved event-free survival vs placebo in resectable gastric/GEJ cancer.

The BREAKWATER trial showed encorafenib, cetuximab, & mFOLFOX6 significantly improved PFS and OS in first-line BRAF V600E-mutant mCRC.

In the phase 2/3 REFRαME-O1 trial, luveltamab tazevibulin showed encouraging responses in patients with ovarian cancer with low to medium FRα expression.

Phase 1b Beamion LUNG-1 trial data at AACR 2025 showed zongertinib yielded responses in pretreated HER2-mutant NSCLC, including TKD and non-TKD mutations.

TAR-200 showed durable disease-free survival in high-risk, BCG-unresponsive papillary NMIBC in SunRISe-1, with high 6/9-month DFS rates and a low cystectomy rate.

Antibody-drug conjugates and their development remains a central theme in ongoing research within the realm of ovarian cancer.

Zamtocabtagene autoleucel induced responses, including durable complete responses, in relapsed/refractory diffuse large B-cell lymphoma.

Obecabtagene autoleucel improved outcomes in relapsed/refractory B-cell acute lymphoblastic leukemia with low-risk CAR-HEMATOTOX scores in the 1/2 FELIX trial.

Encorafenib, cetuximab, and mFOLFOX6 improved ORR over mFOLFOX6 alone in BRAF V600E-mutant mCRC in the BREAKWATER trial.

Encorafenib, cetuximab, and mFOLFOX6 improved overall response rate over mFOLFOX6 alone in BRAF V600E-mutant mCRC, per BREAKWATER data.

Sintilimab plus neoadjuvant CRT improved pathological complete response rates in resectable, locally advanced ESCC, per phase 3 SCIENCE trial.